MORPHOSYS
MorphoSys AG is a biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.
MORPHOSYS
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
1992-01-01
Address:
Planegg, Bayern, Germany
Country:
Germany
Website Url:
http://www.morphosys.com
Total Employee:
251+
Status:
Active
Contact:
+49 89 899270
Total Funding:
635.21 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Font Awesome Domain Not Resolving Nginx
Similar Organizations
Acteryon
Acteryon is a biotechnology company for research and development of new technologies and products based on bacteriophages.
Current Advisors List
Board_member
2015-05-01
Current Employees Featured
Daniel Camus Member & Supervisory Board @ MorphoSys
Member & Supervisory Board
Jens Holstein Chief Financial Officer @ MorphoSys
Chief Financial Officer
2011-05-01
Gerald Möller Chairman & Supervisory Board @ MorphoSys
Chairman & Supervisory Board
Marlies Sproll Chief Scientific Officer @ MorphoSys
Chief Scientific Officer
2005-01-01
Roland Wandeler Chief Operating Officer & CCO @ MorphoSys
Chief Operating Officer & CCO
Marc Cluzel Member & Supervisory Board @ MorphoSys
Member & Supervisory Board
Andreas Pluckthun Co-Founder @ MorphoSys
Co-Founder
Sung Lee Chief Financial Officer @ MorphoSys
Chief Financial Officer
Ann L. Merchant Vice President, Head of Global Supply Chain @ MorphoSys
Vice President, Head of Global Supply Chain
Walter Blättler Member & Supervisory Board @ MorphoSys
Member & Supervisory Board
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-02 | Constellation Pharmaceuticals | Constellation Pharmaceuticals acquired by MorphoSys | 1.7 B USD |
| 2015-05-08 | Lanthio Pharma | Lanthio Pharma acquired by MorphoSys | 22.5 M USD |
| 2010-10-08 | Sloning BioTechnology | Sloning BioTechnology acquired by MorphoSys | N/A |
Investors List
Atlas Venture
Atlas Venture investment in Seed Round - MorphoSys
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-08-20 | Adivo | MorphoSys investment in Seed Round - Adivo | N/A |
Newest Events participated
Participated in Security Document World SDW 2016
on 2016-05-10 as exhibitor
Key Employee Changes
Official Site Inspections
http://www.morphosys.com Semrush global rank: 2.03 M Semrush visits lastest month: 10.39 K
- Host name: 104.18.20.116
- IP address: 104.18.20.116
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MorphoSys"
Org Chart Morphosys - The Official Board
The organizational chart of Morphosys displays its 14 main executives including Arkadius Pichota, Lukas Gilgen and Barbara krebs-pohl. Toggle navigation The Official Board. Search. Search. …See details»
MorphoSys - LinkedIn
Novartis announced that all conditions to close its acquisition of MorphoSys have been fulfilled, securing 79.6% of our total share capital and surpassing the minimum 65% shareholder …See details»
MorphoSys - Crunchbase Company Profile & Funding
MorphoSys may be growing as it has been acquired by Novartis for a significant sum, indicating a strong valuation and interest in its assets. The acquisition by …See details»
MORPHOSYS US INC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MORPHOSYS US INC of Princeton, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Novartis to acquire cancer-focused MorphoSys for $2.9 …
Feb 5, 2024 Drugmaker Novartis AG said it will acquire MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment candidate to ...See details»
MorphoSys AG Company Profile - GlobalData
MorphoSys AG (MorphoSys) is a biopharmaceutical company that develops monoclonal antibodies for therapeutic and research applications, with a focus on the treatment of cancer …See details»
MorphoSys - Company Profile & Staff Directory - ContactOut
MorphoSys began as a research and development technology provider 30 years ago, which positioned us as a valuable partner to pharmaceutical manufacturers worldwide. This …See details»
MorphoSys acquisition - Novartis
Patient organization funding Payments to healthcare professionals Public policy A living wage A safe workplace Animal research Environmental, social and governance ... MorphoSys …See details»
MorphoSys 2025 Company Profile: Valuation, Investors
MorphoSys General Information Description. Operator of a biotechnology firm focusing on the research and development of therapeutic antibodies. The company is dedicated to the …See details»
MorphoSys Company Profile - Office Locations, Competitors
Aug 2, 2024 MorphoSys has 5 employees across 2 locations and €238.28 m in annual revenue in FY 2023. See insights on MorphoSys including office locations, competitors, revenue, …See details»
Org Chart MorphoSys US - The Official Board
The organizational chart of MorphoSys US displays its 3 main executives including Jean-Paul Kress and Jill Robinson. Toggle navigation The Official Board. Search. Search. Search by …See details»
MorphoSys - Overview, News & Similar companies | ZoomInfo.com
Jun 5, 2024 MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution …See details»
MorphoSys - LinkedIn
Novartis announced that all conditions to close its acquisition of MorphoSys have been fulfilled, securing 79.6% of our total share capital and surpassing the minimum 65% shareholder …See details»
Morphosys | Company Overview & News - Forbes
Nov 5, 2023 MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the following segments: Partnered …See details»
INS Learning Center: MorphoSys - Ins1.org
Founded in 1992 in Germany, MorphoSys is dedicated to making innovative biopharmaceuticals to help patients suffering from serious diseases. Based on its leading expertise in antibody, …See details»
More pharma M&A as Novartis snaps up MorphoSys for $2.9bn
Feb 6, 2024 Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion …See details»
MorphoSys and Novartis Sign Delisting Agreement and Intend to …
Media: Thomas Biegi Senior Vice President, Corporate Affairs Tel.: +49 (0)89 / 899 27 26079 thomas.biegi@morphosys.com Eamonn Nolan Senior Director, Corporate Communications & …See details»
MorphoSys - News, Layoffs, Mergers and Acquisitions ... - Usearch
MorphoSys AG has announced a significant change in ownership with The Goldman Sachs Group, Inc. now holding 14.55%: The Goldman Sachs Group, Inc. has acquired a stake in …See details»
Mission, Vision & Core Values of MorphoSys – CBM
Oct 2, 2024 [cbm_blg_rlnkng]MorphoSys is a leading biopharmaceutical company dedicated to transforming patient lives through innovative antibody therapies. Our mission is to develop …See details»
Morphosys
Welcome Back! Login to your account. Email. PasswordSee details»